Transpire Bio’s ANDA for Generic High-Strength Trelegy® Ellipta® Accepted for Filing by the U.S. FDA

SUNRISE, Fla., May 11, 2026 (PR NEWSWIRE) — Transpire Bio Inc., an integrated clinical- stage biopharmaceutical company developing inhaled therapeutics for pulmonary and systemic diseases, today announces that its abbreviated new drug application (ANDA) for fluticasone furoate, umeclidinium, and vilanterol inhalation powder, a generic version of the high-strength Trelegy® Ellipta®1 (200 mcg/62.5 mcg/25 mcg) product, […]